Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) gapped up prior to trading on Tuesday . The stock had previously closed at $13.70, but opened at $14.25. Oruka Therapeutics shares last traded at $14.31, with a volume of 16,258 shares traded.
Wall Street Analysts Forecast Growth
A number of research firms have commented on ORKA. Wedbush restated an "outperform" rating and set a $40.00 target price on shares of Oruka Therapeutics in a research note on Tuesday, November 19th. Stifel Nicolaus started coverage on Oruka Therapeutics in a research report on Friday, October 11th. They issued a "buy" rating and a $49.00 price objective on the stock. Wolfe Research started coverage on Oruka Therapeutics in a report on Tuesday. They issued an "outperform" rating and a $20.00 price target on the stock. Finally, HC Wainwright reissued a "buy" rating and issued a $45.00 target price on shares of Oruka Therapeutics in a report on Friday. Seven investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, Oruka Therapeutics has an average rating of "Buy" and a consensus target price of $39.86.
View Our Latest Analysis on Oruka Therapeutics
Oruka Therapeutics Stock Performance
The firm has a market cap of $399 million, a P/E ratio of -1.82 and a beta of 0.77. The stock has a 50-day simple moving average of $17.74.
Institutional Trading of Oruka Therapeutics
A number of large investors have recently made changes to their positions in the business. AlphaCentric Advisors LLC purchased a new position in Oruka Therapeutics in the fourth quarter worth about $119,000. China Universal Asset Management Co. Ltd. purchased a new stake in Oruka Therapeutics during the 4th quarter valued at $144,000. Charles Schwab Investment Management Inc. purchased a new position in Oruka Therapeutics during the fourth quarter worth $303,000. Geode Capital Management LLC purchased a new stake in shares of Oruka Therapeutics in the third quarter valued at $343,000. Finally, The Manufacturers Life Insurance Company bought a new stake in Oruka Therapeutics in the third quarter worth about $1,037,000. 56.44% of the stock is currently owned by institutional investors.
Oruka Therapeutics Company Profile
(
Get Free Report)
Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.
See Also
Before you consider Oruka Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oruka Therapeutics wasn't on the list.
While Oruka Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
